Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

Sponsor
University Health Network, Toronto
Study ID
NCT06831032
Status
Recruiting
Apply to this trial

Conditions

  • Iliac Nodal Disease
  • Oligorecurrence
  • Para-aortic Lymph Node Metastasis
  • Para-aortic Nodal Disease
  • Prostate Adenocarcinoma

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adaptive radiotherapy using SBRT — RADIATION
    Adaptive External beam radiotherapy using SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25 Gy in 5 fractions ENI to PA nodes (+ common iliac nodes)

Study Details

This prospective, single-arm feasibility study will include patients with prostate cancer that have controlled local disease diagnosed with oligorecurrent para-aortic nodal disease and/or common iliac nodal disease detected by PSMA PET or conventional CT/MRI imaging, and these patients will undergo CT-guided online adaptive SBRT to the tumor and elective SBRT to adjacent at-risk nodal regions.

Key Dates

First listed
Feb 17, 2025
Start date
Jul 7, 2026
Status verified
Mar 2026
Primary completion
Jul 7, 2029
Completion
Jul 7, 2029

Study Design

Enrollment
26 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SBRT delivered with CBCT-guided online adaptive RT
    Patients will undergo CT guided online adaptive SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25Gy in 5 fractions ENI to PA nodes (+/- pelvic nodes).

Primary Outcome Measure

Quantify adverse events using CTCAE v5.0 [ Time Frame: 2 years ]

Central Contacts

Related Studies